Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

ASCO Provisional Clinical Opinion: Epidermal Growth Factor Receptor Mutation Testing in Practice

1 May 2011

Abstract excerpt

ASCO has recently provided guidance on emerging data on EGFR testing for the purpose of selecting first-line therapy for persons with advanced NSCLC through its Provisional Clinical Opinion.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Gastric Cancer Management and Outcomes
Share to HER2/EGFR in Cancer Research
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21886505
DOI: 10.1200/jop.2010.000166

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

ASCO Provisional Clinical Opinion: Epidermal Growth Factor Receptor Mutation Testing in PracticePMID 21886505Read ↗

American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor (EGFR) Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.Semantic proximity Read ↗

Dealing with NSCLC EGFR mutation testing and treatment: A comprehensive review with an Italian real-world perspective.Semantic proximity Read ↗

The expanding capability and clinical relevance of molecular diagnostic technology to identify and evaluate EGFR mutations in advanced/metastatic NSCLC.Semantic proximity Read ↗

Biomarker Testing for Actionable Alterations in NSCLC-Perspectives from US-Based Academic and Community Oncologists: A Podcast.Semantic proximity Read ↗

[Molecular testing clinical progress for EGFR mutation and ALK rearrangement of lung cancer based on the guideline from IASLC/CAP/AMP].Semantic proximity Read ↗

Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer in the Real-World Setting in Central Europe: The INSIGHT Study.Semantic proximity Read ↗

EGFR testing in lung cancer is ready for prime time.Semantic proximity Read ↗

EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors.Semantic proximity Read ↗

Utilisation and Determinants of Epidermal Growth Factor Receptor Mutation Testing in Patients with Non-small Cell Lung Cancer in Routine Clinical Practice: A Global Systematic Review.Semantic proximity Read ↗

Second Line Treatment Decision as Per Standard of Care or Foundation Medicine in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Patient Characteristics, Testing and Treatment Patterns, and Outcomes in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multinational, Real-World Study.Semantic proximity Read ↗

HER2-Mutant Non-Small Cell Lung Cancer Podcast: Finding Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.